Biotech Showcase 2015 EBD Group Demy-Colton Image Map
Share:
Email this page Share this on LinkedIn Share this on Twitter

Biotech Showcase™ 2015 Press Releases

January 27, 2015Biotech Showcase™ 2015 surpasses all previous investor attendance, partnering numbers The seventh annual Biotech Showcase investor conference wrapped up the week of January 12 in San Francisco with the highest number of delegates in attendance since its founding. More than 2,100 executive-level delegates representing qualified private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives attended from...  more ►

January 2, 2015Biotech Showcase™ 2015 kicks off in one week
Over 2,000 life science executive dealmakers expected to attend
The seventh annual Biotech Showcase investor conference takes place in just over one week on January 12–14, 2015 in San Francisco, CA at Parc 55 Wyndham San Francisco - Union Square. Biotech Showcase is an investor conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and ph...  more ►

November 18, 2014Seventh Annual Biotech Showcase™ to be held in San Francisco January 12–14, 2015-- Record number of Life Science Investor meetings expected
The seventh annual Biotech Showcase investor conference will be held January 12–14, 2015 in San Francisco, CA at Parc 55 Wyndham San Francisco - Union Square. The event brings executive-level delegates representing top public and private investment firms with the goal to meet management teams of biotechnology and life science companies, including therapeutic companies, sp...  more ►


partnering360® Blog

May 28, 2015 Put the life science ecosystem to work for you in Boston ENGAGE and DE-RISK. These two terms describe the enormous task of drug development, which is best achieved by wide engagement across the life science ecosystem, to distribute risk that can otherwise be overwhelming. Add to that description “DISRUPT.” There is an increasing number of industry... more ►

May 18, 2015 Where Are They Now? The Life Sciences Report Small-Cap Watchlist Edition Guest post by Jim Patrick, Publisher, The Life Sciences Report It’s been four months since Streetwise Reports’ The Life Sciences Report‘s 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase™ in San Francisco. Although our portfolio tracker follows the basket of... more ►

May 13, 2015 Bar raised for CAR-T cell therapy deal and IPO values Guest post by Raveena Bhambra, Senior Analyst at Current Partnering If you’ve not heard of CAR-T cell therapy and you’re based in the biotech industry, where have you been? Over the past year the technology has become one of the most talked about and anticipated technologies as promising... more ►

May 11, 2015 CRO report identifies trends and opportunities in the life science sector Guest post by Natalie Morrison, Senior Reporter at BioPharm Insight BioPharm Insight’s (BPI) 1Q15 CRO report, compiled by analyst Peter Murphy, delves into trends and opportunities in the life sciences services sector. The report notes oncology was the most trialed indication, totaling 20% of all... more ►

May 5, 2015 Help us reach our 30,000 members milestone and you could be a winner! partnering360®, your life science dealmaker network, is about to celebrate a milestone. We are nearing our 30,000th member, and as part of the celebration, we want to offer you a chance to win a FREE ticket to an EBD Group event. Simply encourage your colleagues and associates to join you as member... more ►



partnering360:Insight Latest headlines from partnering360:Insight

May 27, 2015 Atlas Venture: It takes a village Atlas Venture pioneered the “built-to-buy” business model a few years ago knowing that it takes a village to build a successful biotech company—assuming that village is populated by innovative scientists, serial biotech entrepreneurs, risk-tolerant investors and biopharma partners with the wherewithal to take drugs from clinical development to commercialization. more ►

May 19, 2015 Aisling Capital: Strategies to survive the boom The biotech industry survived the financial valley of death of the past decade and emerged into a figurative land of milk and honey. Rejoice, but remain vigilant. These boom times are nearly as dangerous as the cash-strapped recent past. more ►

May 19, 2015 Lysosomal Therapeutics: Brilliant science, brilliant networks A cure for Parkinson’s disease may be possible if the research at Lysosomal Therapeutics, Inc. (LIT) advances as expected. Unlike therapies that treat the symptoms of this disease, LTI is developing a novel platform that addresses the root cause of the disease by working at the intersection of lysosomal storage disorders and neurodegenerative diseases. more ►

March 11, 2015 Sanofi , Medicen and other Paris Region clusters are leading the collaborative effort to bring ICT for Health innovation to the patient “We are working here in the Paris region to combine all the clusters that are linked to ICT for Health,” said Meunier. In particular, the three different clusters with three different technological areas of expertise involved are Medicen, Cap Digital, a software company, and Systematique Paris region, focused on ICT for Health. more ►

March 11, 2015 Targeting cancer stem cells may be key to a cure Something has been left behind in the billion-dollar "frothy" excitement over immuno-oncology therapies: recurrence of cancer and the inability to treat metastatic cancer. more ►



Arrow Up


 
 
See more upcoming conferences ►

EBD Group's Family of Events

© 2009–2015 EBD Group, Inc.
Privacy Policy
Terms of Use
Biotech Showcase 2015 EBD Group Demy-Colton Image Map